Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 171

1.

Observational and genetic plasma YKL-40 and cancer in 96,099 individuals from the general population.

Kjaergaard AD, Nordestgaard BG, Johansen JS, Bojesen SE.

Int J Cancer. 2015 Jun 11. doi: 10.1002/ijc.29638. [Epub ahead of print]

PMID:
26095694
2.

Prediction of treatment response to adalimumab: a double-blind placebo-controlled study of circulating microRNA in patients with early rheumatoid arthritis.

Krintel SB, Dehlendorff C, Hetland ML, Hørslev-Petersen K, Andersen KK, Junker P, Pødenphant J, Ellingsen T, Ahlquist P, Lindegaard HM, Linauskas A, Schlemmer A, Dam MY, Hansen I, Horn HC, Jørgensen A, Raun J, Ammitzbøll CG, Østergaard M, Stengaard-Pedersen K, Johansen JS.

Pharmacogenomics J. 2015 May 5. doi: 10.1038/tpj.2015.30. [Epub ahead of print]

PMID:
25939484
3.

Elevated plasma YKL-40, lipids and lipoproteins, and ischemic vascular disease in the general population.

Kjaergaard AD, Johansen JS, Bojesen SE, Nordestgaard BG.

Stroke. 2015 Feb;46(2):329-35. doi: 10.1161/STROKEAHA.114.007657.

PMID:
25624368
4.

Serum YKL-40 in risk assessment for colorectal cancer: a prospective study of 4,496 subjects at risk of colorectal cancer.

Johansen JS, Christensen IJ, Jørgensen LN, Olsen J, Rahr HB, Nielsen KT, Laurberg S, Brünner N, Nielsen HJ.

Cancer Epidemiol Biomarkers Prev. 2015 Mar;24(3):621-6. doi: 10.1158/1055-9965.EPI-13-1281. Epub 2015 Jan 18.

PMID:
25597749
5.

Serum YKL-40: a new independent prognostic marker for skeletal complications in patients with multiple myeloma.

Mylin AK, Abildgaard N, Johansen JS, Heickendorff L, Kreiner S, Waage A, Turesson I, Gimsing P; for the Nordic Myeloma Study Group.

Leuk Lymphoma. 2015 Feb 11:1-10. [Epub ahead of print]

PMID:
25573204
6.

Circulating tumor necrosis factor-α and YKL-40 level is associated with remission status following salvage therapy in relapsed non-Hodgkin lymphoma.

El-Galaly TC, Bilgrau AE, Gaarsdal E, Klausen TW, Pedersen LM, Nielsen KR, Bæch J, Bøgsted M, Dybkær K, Johansen JS, Johnsen HE.

Leuk Lymphoma. 2015 Feb 24:1-3. [Epub ahead of print] No abstract available.

PMID:
25563560
7.

CRP genotype and haplotype associations with serum C-reactive protein level and DAS28 in untreated early rheumatoid arthritis patients.

Ammitzbøll CG, Steffensen R, Bøgsted M, Hørslev-Petersen K, Hetland ML, Junker P, Johansen JS, Pødenphant J, Østergaard M, Ellingsen T, Stengaard-Pedersen K.

Arthritis Res Ther. 2014 Oct 31;16(5):475. doi: 10.1186/s13075-014-0475-3.

8.

Serum YKL-40 for monitoring myocardial ischemia after revascularization in patients with stable coronary artery disease.

Harutyunyan M, Johansen JS, Mygind ND, Reuter SB, Kastrup J.

Biomark Med. 2014;8(8):977-87. doi: 10.2217/bmm.14.20.

PMID:
25343670
9.

Plasma YKL-40 in Inuit and Danes.

Nøjgaard C, Johansen JS, Bjerregaard P, Bojesen SE, Becker U.

Alcohol Alcohol. 2015 Jan;50(1):11-7. doi: 10.1093/alcalc/agu072. Epub 2014 Oct 20.

PMID:
25332349
10.

Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab.

Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P, Holländer NH, Keldsen N, Hansen TF, Jensen BB, Høgdall EV, Jensen BV, Johansen JS.

PLoS One. 2014 Oct 15;9(10):e109430. doi: 10.1371/journal.pone.0109430. eCollection 2014.

11.

YKL-40 and alcoholic liver and pancreas damage and disease in 86,258 individuals from the general population: cohort and mendelian randomization studies.

Kjaergaard AD, Bojesen SE, Nordestgaard BG, Johansen JS.

Clin Chem. 2014 Nov;60(11):1429-40. doi: 10.1373/clinchem.2014.229096. Epub 2014 Sep 15.

PMID:
25225167
12.

FCGR polymorphisms and cetuximab efficacy in chemorefractory metastatic colorectal cancer: an international consortium study.

Geva R, Vecchione L, Kalogeras KT, Jensen BV, Lenz HJ, Yoshino T, Paez D, Montagut C, Souglakos J, Cappuzzo F, Cervantes A, Frattini M, Fountzilas G, Johansen JS, Høgdall EV, Zhang W, Yang D, Yamazaki K, Nishina T, Papamichael D, Vincenzi B, Macarulla T, Loupakis F, De Schutter J, Spindler KL, Pfeiffer P, Ciardiello F, Piessevaux H, Tejpar S.

Gut. 2015 Jun;64(6):921-8. doi: 10.1136/gutjnl-2014-307234. Epub 2014 Jul 10.

PMID:
25011934
13.

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan.

Schou JV, Rossi S, Jensen BV, Nielsen DL, Pfeiffer P, Høgdall E, Yilmaz M, Tejpar S, Delorenzi M, Kruhøffer M, Johansen JS.

PLoS One. 2014 Jun 18;9(6):e99886. doi: 10.1371/journal.pone.0099886. eCollection 2014.

14.

Antibody directed against human YKL-40 increases tumor volume in a human melanoma xenograft model in scid mice.

Salamon J, Hoffmann T, Elies E, Peldschus K, Johansen JS, Lüers G, Schumacher U, Wicklein D.

PLoS One. 2014 Apr 21;9(4):e95822. doi: 10.1371/journal.pone.0095822. eCollection 2014.

15.

Brain barriers and a subpopulation of astroglial progenitors of developing human forebrain are immunostained for the glycoprotein YKL-40.

Bjørnbak C, Brøchner CB, Larsen LA, Johansen JS, Møllgård K.

J Histochem Cytochem. 2014 May;62(5):369-88. doi: 10.1369/0022155414528514. Epub 2014 Mar 4.

16.

Plasma YKL-40 in patients with metastatic colorectal cancer treated with first line oxaliplatin-based regimen with or without cetuximab: RESULTS from the NORDIC VII Study.

Tarpgaard LS, Guren TK, Glimelius B, Christensen IJ, Pfeiffer P, Kure EH, Sorbye H, Ikdahl T, Yilmaz M, Johansen JS, Tveit KM.

PLoS One. 2014 Feb 3;9(2):e87746. doi: 10.1371/journal.pone.0087746. eCollection 2014. Erratum in: PLoS One. 2014;9(5):e98836.

17.

MicroRNA biomarkers in whole blood for detection of pancreatic cancer.

Schultz NA, Dehlendorff C, Jensen BV, Bjerregaard JK, Nielsen KR, Bojesen SE, Calatayud D, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK, Johansen JS.

JAMA. 2014 Jan 22-29;311(4):392-404. doi: 10.1001/jama.2013.284664.

PMID:
24449318
18.

A treat-to-target strategy with methotrexate and intra-articular triamcinolone with or without adalimumab effectively reduces MRI synovitis, osteitis and tenosynovitis and halts structural damage progression in early rheumatoid arthritis: results from the OPERA randomised controlled trial.

Axelsen MB, Eshed I, Hørslev-Petersen K, Stengaard-Pedersen K, Hetland ML, Møller J, Junker P, Pødenphant J, Schlemmer A, Ellingsen T, Ahlquist P, Lindegaard H, Linauskas A, Dam MY, Hansen I, Horn HC, Ammitzbøll CG, Jørgensen A, Krintel SB, Raun J, Krogh NS, Johansen JS, Østergaard M; OPERA study group.

Ann Rheum Dis. 2015 May;74(5):867-75. doi: 10.1136/annrheumdis-2013-204537. Epub 2014 Jan 10.

PMID:
24412895
19.

Plasma YKL-40 and all-cause mortality in patients with chronic obstructive pulmonary disease.

Holmgaard DB, Mygind LH, Titlestad IL, Madsen H, Pedersen SS, Johansen JS, Pedersen C.

BMC Pulm Med. 2013 Dec 30;13:77. doi: 10.1186/1471-2466-13-77.

20.

Genetic variants in CHI3L1 influencing YKL-40 levels: resequencing 900 individuals and genotyping 9000 individuals from the general population.

Kjaergaard AD, Johansen JS, Nordestgaard BG, Bojesen SE.

J Med Genet. 2013 Dec;50(12):831-7. doi: 10.1136/jmedgenet-2013-101908. Epub 2013 Sep 23.

PMID:
24062521
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk